KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.95

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Johannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, Marlena Surowka, Sylvia Herter, Katharina Lechner, James Relf, Stefanie Briner, Ahmet Varol, Birte Appelt, Ioana Domocos, Valeria Nicolini, Miriam Bez, Esther Bommer, Silvia Jenni, Anne Schoenle, Marine Le Clech, Sara Colombetti, Christian Klein, Pablo Umaña, Pontus Lundberg, Koorosh Korfi, Alessia Bottos, Marina Bacac

Blood 146(15) 1824-1836

PMID40749164
PMCIDPMC12824690
DOI10.1182/blood.2025028863
发表日期2025-08-01
入排依据:The record is a preclinical study, not an original formal-result report of a human Phase III/IIIb or Phase II/III randomized trial. The abstract details only preclinical investigations in animal models and translational studies with patient-derived cells, without reporting the primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) from a definitive human trial.
入排复审未纳入:The record is a preclinical study, not an original formal-result report of a human Phase III/IIIb or Phase II/III randomized trial. The abstract details only preclinical investigations in animal models and translational studies with patient-derived cells, without reporting the primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) from a definitive human trial.
摘要

摘要

T-cell engagers (TCEs) are transformative therapeutics in hematologic malignancies, including non-Hodgkin lymphoma. Initially approved for relapsed/refractory disease settings, TCEs are now explored in first-line and second-line settings, often combined with standard-of-care (SOC) treatments, including chemotherapy and antibody-drug conjugates. This study investigates glofitamab (CD20×CD3 TCE) combinations in preclinical humanized lymphoma models, addressing heterogeneity of tumor antigen expression, immune evasion, and T-cell exhaustion. Combining glofitamab with R-CHP-Pola (rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin) chemotherapy or Pola demonstrated strong synergistic antitumor efficacy with rapid tumor regression and reduced tumor cell proliferation. Glofitamab combination with gemcitabine/oxaliplatin also demonstrated strong efficacy, enhancing intratumor T-cell number, activation, and reduced exhaustion. These combinations were particularly advantageous in models with low and heterogeneous CD20 expression, facilitating rapid tumor debulking and elimination of CD20-low/CD20- cells. Translational studies with patient-derived peripheral blood mononuclear cells receiving glofitamab combination with chemotherapies demonstrated sustained T-cell functionality throughout extended treatment cycles. Novel chemotherapy-free combinations, including CD19-targeted 4-1BBL and CD19-CD28, amplified glofitamab activity, especially in CD20 high- and homogenous-expressing tumor models, with dual costimulatory approaches revealing synergy. In addition, the combination with checkpoint inhibitors (programmed cell death protein 1/Lag3-bispecific antibody) and regulatory T-cell depletion (α-CD25) emerged as promising approaches for enhanced efficacy and to sustain T-cell functionality. These findings highlight the versatility of glofitamab when integrated with SOC and innovative combinations, addressing resistance and improving patient outcomes. The preclinical investigations provide a strong foundation for ongoing and future clinical trials, emphasizing the need to tailor TCE-based combination therapies to maximize efficacy while minimizing toxicity in lymphoma treatment. These trials were registered at www.clinicaltrials.gov as #NCT04408638 and NCT03467373.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。